A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease

The metabotropic glutamate receptor 5‐negative allosteric modulator dipraglurant reduces levodopa‐induced dyskinesia in the MPTP‐macaque model. The objective of this study was to assess the safety, tolerability (primary objective), and efficacy (secondary objective) of dipraglurant on levodopa‐induced dyskinesia in Parkinson's disease (PD).

[1]  P. Vieregge,et al.  Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study , 2005, European journal of neurology.

[2]  Regina Katzenschlager,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[3]  O. Rascol,et al.  Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. , 2014, Parkinsonism & related disorders.

[4]  O. Rascol.  Medical treatment of levodopa-induced dyskinesias. , 2000, Annals of neurology.

[5]  A. Hsu,et al.  The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. , 2007, Current clinical pharmacology.

[6]  Klaus Seppi,et al.  Which dyskinesia scale best detects treatment response? , 2013, Movement disorders : official journal of the Movement Disorder Society.

[7]  A. Destée,et al.  AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[8]  Qin Li,et al.  The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model , 2014, Movement disorders : official journal of the Movement Disorder Society.

[9]  E. Bézard,et al.  Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.